RT Journal Article
SR Electronic
T1 Signatures of COVID-19 severity and immune response in the respiratory tract microbiome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.02.21254514
DO 10.1101/2021.04.02.21254514
A1 Carter Merenstein
A1 Guanxiang Liang
A1 Samantha A. Whiteside
A1 Ana G. Cobián-Güemes
A1 Madeline S. Merlino
A1 Louis J. Taylor
A1 Abigail Glascock
A1 Kyle Bittinger
A1 Ceylan Tanes
A1 Jevon Graham-Wooten
A1 Layla A. Khatib
A1 Ayannah S. Fitzgerald
A1 Shantan Reddy
A1 Amy E. Baxter
A1 Josephine R. Giles
A1 Derek A. Oldridge
A1 Nuala J. Meyer
A1 E. John Wherry
A1 John E. McGinniss
A1 Frederic D. Bushman
A1 Ronald G. Collman
YR 2021
UL http://medrxiv.org/content/early/2021/04/05/2021.04.02.21254514.abstract
AB Rationale Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease.Objective To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes.Methods and Measurements We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Anelloviridae and Redondoviridae were quantified by qPCR, and immune features were characterized by lymphocyte/neutrophil (L/N) ratios and deep immune profiling of peripheral blood mononuclear cells (PBMC).Main Results COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Staphylococcus. Anelloviridae and Redondoviridae showed more frequent colonization and higher titers in severe disease. Machine learning analysis demonstrated that integrated features of the microbiome at early sampling points had high power to discriminate ultimate level of COVID-19 severity.Conclusions The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Penn Center for Research on Coronaviruses and Other Emerging Pathogens and NIH grant R33-HL137063 (R.G.C., F.D.B.). E.J.W. was supported by NIH grants AI105343, AI082630, the Allen Institute for Immunology and the Parker Institute for Cancer Immunotherapy. J.R.G. was supported by the NIH (T32 CA009140) and a Cancer Research Institute-Mark Foundation FellowshipAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Following informed consent obtained under protocol #823392 approved by the University of Pennsylvania IRB, samples were collected at the Hospital of the University of PennsylvaniaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull data availability will be made upon final publication, with relevant data obtainable from NCBI sequence read archive and from online supplementary files.